文献速递重症综合管理与镇静镇痛创伤与烧伤

胍法辛对普外与创伤ICU患者谵妄的影响:一项先导性随机临床试验

The Effect of Guanfacine on Delirium in Surgical and Trauma ICU Patients: A Pilot Randomized Clinical Trial.
PubMed 文献 · Crit Care Med · 2026-11-11
一句话结论在普外与创伤ICU谵妄成人中,每晚胍法辛2 mg较安慰剂未显著改善校正后谵妄与无昏迷天数,但可行性指标良好,支持推进多中心试验。

该单中心、随机、双盲、安慰剂对照先导试验于2020年11月至2023年2月在阿拉巴马大学伯明翰医院普外与创伤ICU开展,纳入100例经CAM-ICU确认谵妄的危重成人,1:1随机接受胍法辛2 mg或匹配安慰剂每晚一次,最长14天或至ICU出科或谵妄缓解。主要可行性指标多数达标:方案依从性100%、保留率100%、数据完整性100%;招募受COVID-19疫情影响,活跃招募期实际为0.9例/周。未校正分析中胍法辛组谵妄与无昏迷天数中位数高于安慰剂组(2天[IQR 0-6] vs 1天[IQR 0-4],p=0.02),但校正预设基线协变量后无统计学显著性;ICU与住院时间、机械通气时长组间无显著差异,未观察到血流动力学差异或安全性问题。作者认为该先导研究支持开展确定性试验。

要点

  • 100例CAM-ICU确认谵妄的普外/创伤ICU成人随机接受胍法辛2 mg或安慰剂每晚一次,最长14天或至ICU出科或谵妄缓解。
  • 可行性达标:方案依从性100%、保留率100%、数据完整性100%;活跃招募期招募率0.9例/周,受COVID-19疫情影响。
  • 未校正分析胍法辛组谵妄与无昏迷天数中位数2天(IQR 0-6)vs 安慰剂组1天(IQR 0-4),p=0.02;校正预设基线协变量后无统计学显著性。
  • ICU与住院时间、机械通气时长组间无显著差异;未观察到血流动力学差异或安全性问题。
  • 作者认为未校正的谵妄与无昏迷天数差异及良好安全性支持推进多中心试验。

适用人群与场景

  • 普外与创伤ICU的危重成人,经Confusion Assessment Method-ICU确认谵妄后纳入。
  • 单中心研究,地点为阿拉巴马大学伯明翰医院普外与创伤ICU。

诊断标准与关键阈值

  • 以Confusion Assessment Method-ICU确认谵妄作为纳入条件。

处置流程与药物剂量

  • 胍法辛2 mg或匹配安慰剂,每晚给药一次,最长14天,或至ICU出科或谵妄缓解。

研究设计与关键结果

  • 单中心、随机、双盲、安慰剂对照先导试验,2020年11月至2023年2月,纳入100例CAM-ICU确认谵妄的危重成人,1:1随机至胍法辛或安慰剂。
  • 主要可行性终点:方案依从性100%(目标≥90%)、保留率100%(目标≥80%)、数据完整性100%(目标≥95%);活跃招募期招募率0.9例/周,受COVID-19疫情影响。
  • 未校正分析:胍法辛组谵妄与无昏迷天数中位数2天(IQR 0-6)vs 安慰剂组1天(IQR 0-4),p=0.02;校正预设基线协变量后无统计学显著性。
  • ICU与住院时间及机械通气时长组间无显著差异;未观察到血流动力学差异或安全性问题。

证据类型、等级与局限

  • 证据类型:单中心、随机、双盲、安慰剂对照先导试验。
  • 局限:招募受COVID-19疫情影响,活跃招募期招募率为0.9例/周;校正预设基线协变量后谵妄与无昏迷天数差异无统计学显著性;作者指出需进一步评估(warrants further evaluation)。

对床旁实践的改变

  • 作者认为未校正的谵妄与无昏迷天数差异及良好安全性支持推进多中心试验。
  • 该先导试验未提供胍法辛用于ICU谵妄的推荐;原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the feasibility of conducting a randomized controlled trial investigating guanfacine for ICU delirium, including assessment of recruitment, retention, protocol adherence, and data completeness, while estimating treatment effects to inform future trial design.

DESIGN: Single-center, randomized, double-blind, placebo-controlled pilot trial conducted from November 2020 to February 2023.

SETTING: Surgical and Trauma ICUs at the University of Alabama at Birmingham Hospital.

PATIENTS: One hundred critically ill adults with Confusion Assessment Method-ICU-confirmed delirium randomized 1:1 to guanfacine or placebo.

INTERVENTIONS: Patients received 2 mg guanfacine or matching placebo nightly for up to 14 days, or until ICU discharge or delirium resolution.

MEASUREMENTS AND MAIN RESULTS: Primary feasibility outcomes included protocol adherence (target ≥ 90%), retention (target ≥ 80%), recruitment rate (target ≥ 2 patients/mo), and data completeness (target ≥ 95%). Most feasibility targets were achieved: protocol adherence was 100%, retention was 100%, and data completeness was 100%. Recruitment was significantly impacted by COVID-19 pandemic disruptions, achieving 0.9 patients/wk during active recruitment periods.For clinical outcomes, in unadjusted analyses, median delirium and coma-free days were higher with guanfacine than placebo (2 [interquartile range [IQR], 0-6] vs. 1 [IQR, 0-4]; p = 0.02); however, this association was not statistically significant after adjustment for prespecified baseline covariates. ICU and hospital length of stay and duration of mechanical ventilation did not differ significantly between groups. No hemodynamic differences or safety concerns were observed.

CONCLUSIONS: This pilot study successfully supports feasibility for a definitive trial, with excellent protocol adherence, adequate retention, and preliminary signals that warrant further evaluation. Although adjusted analyses were not statistically significant, the observed unadjusted difference in delirium and coma-free days and favorable safety profile support progression to a multicenter trial informed by these pilot estimates.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Barker AB, Kim HS, Chapleau CA, et al. The Effect of Guanfacine on Delirium in Surgical and Trauma ICU Patients: A Pilot Randomized Clinical Trial. Crit Care Med. 2026. PMID: 43012620. doi:10.1097/CCM.0000000000007448

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。